Factors associated with early response to olanzapine and clinical and functional outcomes of early responders treated for schizophrenia in the People’s Republic of China

References

• FalkaiPWobrockTLiebermanJGlenthojBGattazWFMöllerH-JWorld Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: acute treatment of schizophreniaWorld J Biol Psychiatry20056313219116173147
   PubMed Web of Science ®Google Scholar
• MathersCBoermaTFatDMThe Global Burden of Disease: 2004 UpdateGeneva, SwitzerlandWorld Health Organization Press2008
   Google Scholar
• BuckleyPFWirshingDABhushanPPierreJMResnickSAWirshingWCLack of insight in schizophrenia: impact on treatment adherenceCNS Drugs200721212914117284095
   PubMed Web of Science ®Google Scholar
• KaragianisJNovickDPecenakJWorldwide-Schizophrenia Outpatient Health Outcomes (W-SOHO): baseline characteristics of pan-regional observational data from more than 17,000 patientsInt J Clin Pract200963111578158819780867
   PubMed Web of Science ®Google Scholar
• MarwahaSJohnsonSSchizophrenia and employmentSoc Psychiatry Psychiatr Epidemiol200439533734915133589
   PubMed Web of Science ®Google Scholar
• FalkaiPWobrockTLiebermanJGlenthojBGattazWFMöllerH-JWorld Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophreniaWorld J Biol Psychiatry20067154016509050
   PubMed Web of Science ®Google Scholar
• LehmanAFLiebermanJADixonLBPractice guideline for the treatment of patients with schizophrenia, second editionAm J Psychiatry2004161Suppl 215615000267
   PubMed Web of Science ®Google Scholar
• LeuchtSKomossaKRummel-KlugeCA meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophreniaAm J Psychiatry2009166215216319015230
   PubMed Web of Science ®Google Scholar
• LiebermanJAStroupTSMcEvoyJPEffectiveness of antipsychotic drugs in patients with chronic schizophreniaN Engl J Med2005353121209122316172203
   PubMed Web of Science ®Google Scholar
• Rummel-KlugeCKomossaKSchwarzSHead-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysisSchizophr Res20101232–322523320692814
   PubMed Web of Science ®Google Scholar
• LeuchtSKisslingWDavisJMSecond-generation antipsychotics for schizophrenia: can we resolve the conflict? Psychol Med200939101591160219335931
   PubMed Web of Science ®Google Scholar
• KiviniemiMSuvisaariJKoivumaa-HonkanenHHäkkinenUIsohanniMHakkoHAntipsychotics and mortality in first-onset schizophrenia: prospective Finnish register study with 5-year follow-upSchizophr Res2013150127428023953217
   PubMed Web of Science ®Google Scholar
• YaoXWuJLiuLYeWXueHMontgomeryWMedication use patterns and adherence after initiating antipsychotics treatment for patients with schizophrenia in Tianjin, ChinaValue Health2013167A554
   Web of Science ®Google Scholar
• OlivaresJMThirunavukarasuMKulkarniJZhangHYZhangMZhangFPsychiatrists’ awareness of partial and nonadherence to antipsychotic medication in schizophrenia: results from an Asia-Pacific surveyNeuropsychiatr Dis Treat201391163117023976858
   PubMed Web of Science ®Google Scholar
• Ayuso-GutiérrezJLdel Río VegaJMFactors influencing relapse in the long-term course of schizophreniaSchizophr Res1997282–31992069468354
   PubMed Web of Science ®Google Scholar
• RobinsonDWoernerMGAlvirJMPredictors of relapse following response from a first episode of schizophrenia or schizoaffective disorderArch Gen Psychiatry199956324124710078501
   PubMed Web of Science ®Google Scholar
• LawMRSoumeraiSBRoss-DegnanDAdamsASA longitudinal study of medication nonadherence and hospitalization risk in schizophreniaJ Clin Psychiatry2008691475318312037
   PubMed Web of Science ®Google Scholar
• WeidenPJKozmaCGroggALocklearJPartial compliance and risk of rehospitalization among California Medicaid patients with schizophreniaPsychiatr Serv200455888689115292538
   PubMed Web of Science ®Google Scholar
• LacroJDunnLDolderCLeckbandSJesteDPrevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literatureJ Clin Psychiatry2002631089290912416599
   PubMed Web of Science ®Google Scholar
• Ascher-SvanumHZhuBFariesDELacroJPDolderCRPengXAdherence and persistence to typical and atypical antipsychotics in the naturalistic treatment of patients with schizophreniaPatient Prefer Adherence20082677719920946
   PubMedGoogle Scholar
• TunisSLFariesDEStenslandMDHayDPKinonBJAn examination of factors affecting persistence with initial antipsychotic treatment in patients with schizophreniaCurr Med Res Opin20072319710417257471
   PubMed Web of Science ®Google Scholar
• LangKMeyersJKornJMedication adherence and hospitalization among patients with schizophrenia treated with antipsychoticsPsychiatr Serv201061121239124721123409
   PubMed Web of Science ®Google Scholar
• Ascher-SvanumHNyhuisAWStaufferVReasons for discontinuation and continuation of antipsychotics in the treatment of schizophrenia from patient and clinician perspectivesCurr Med Res Opin201026102403241020812791
   PubMed Web of Science ®Google Scholar
• CaseMStaufferVLAscher-SvanumHThe heterogeneity of antipsychotic response in the treatment of schizophreniaPsychol Med20114161291130020925971
   PubMed Web of Science ®Google Scholar
• LipkovichIADeberdtWCsernanskyJGDefining “good” and “poor” outcomes in patients with schizophrenia or schizoaffective disorder: a multidimensional data-driven approachPsychiatry Res20091702–316116719897252
   PubMed Web of Science ®Google Scholar
• NordonCRouillonFAzorinJMBarryCUrbachMFalissardBTrajectories of antipsychotic response in drug-naive schizophrenia patients: results from the 6-month ESPASS follow-up studyActa Psychiatr Scand2014129211612523600715
   PubMed Web of Science ®Google Scholar
• SchennachRMeyerSSeemüllerFResponse trajectories in “real-world” naturalistically treated schizophrenia patientsSchizophr Res20121391–321822422658528
   PubMed Web of Science ®Google Scholar
• AgidOKapurSArenovichTZipurskyRBDelayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejectedArch Gen Psychiatry200360121228123514662555
   PubMed Web of Science ®Google Scholar
• AgidOSiuCOPappadopulosEVanderburgDRemingtonGEarly prediction of clinical and functional outcome in schizophreniaEur Neuropsychopharmacol201323884285123141372
   PubMed Web of Science ®Google Scholar
• Ascher-SvanumHNyhuisAWFariesDEKinonBJBakerRWShekharAClinical, functional, and economic ramifications of early nonresponse to antipsychotics in the naturalistic treatment of schizophreniaSchizophr Bull20083461163117118156640
   PubMed Web of Science ®Google Scholar
• Ascher-SvanumHZhaoFDetkeHEarly response predicts subsequent response to olanzapine long-acting injection in a randomized, double-blind clinical trial of treatment for schizophreniaBMC Psychiatry201111115221943257
   PubMed Web of Science ®Google Scholar
• KinonBJChenLAscher-SvanumHPredicting response to atypical antipsychotics based on early response in the treatment of schizophreniaSchizophr Res20081021–323024018423985
   PubMed Web of Science ®Google Scholar
• KinonBJChenLAscher-SvanumHEarly response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophreniaNeuropsychopharmacology201035258159019890258
   PubMed Web of Science ®Google Scholar
• KinonBJChenLAscher-SvanumHChallenging the assumption that improvement in functional outcomes is delayed relative to improvement in symptoms in the treatment of schizophreniaSchizophr Res2010118117618220080036
   PubMed Web of Science ®Google Scholar
• TreuerTHoffmannVPChenAK-PFactors associated with weight gain during olanzapine treatment in patients with schizophrenia or bipolar disorder: results from a six-month prospective, multinational, observational studyWorld J Biol Psychiatry2009104 Pt 372974019606406
   PubMed Web of Science ®Google Scholar
• GuyWECDEU Assessment Manual for PsychopharmacologyRockville, MD, USAUS Department of Health, Education, and Welfare1976
   Google Scholar
• BrousseGMearyABlancOLançonCLlorcaPMLeboyerMClinical predictors of response to olanzapine or risperidone during acute episode of schizophreniaPsychiatry Res20101791121820472305
   PubMed Web of Science ®Google Scholar
• HaroJMEdgellETNovickDEffectiveness of antipsychotic treatment for schizophrenia: 6-month results of the Pan-European Schizophrenia Outpatient Health Outcomes (SOHO) studyActa Psychiatr Scand2005111322023115701107
   PubMed Web of Science ®Google Scholar
• SchennachRRiesbeckMMayrAShould early improvement be re-defined to better predict the maintenance of response in first-episode schizophrenia patients? Acta Psychiatr Scand2013127647448122957829
   PubMed Web of Science ®Google Scholar
• Schennach-WolffRJägerMMayrAPredictors of response and remission in the acute treatment of first-episode schizophrenia patients – is it all about early response? Eur Neuropsychopharmacol201121537037821255982
   PubMed Web of Science ®Google Scholar
• Schennach-WolffRMeyerSSeemüllerFInfluencing factors and predictors of early improvement in the acute treatment of schizophrenia and schizophrenia spectrum disorderJ Psychiatr Res201145121639164721862035
   PubMed Web of Science ®Google Scholar
• PerkinsDLiebermanJGuHPredictors of antipsychotic treatment response in patients with first-episode schizophrenia, schizoaffective and schizophreniform disordersBr J Psychiatry2004185182415231551
   PubMed Web of Science ®Google Scholar
• EmsleyRChilizaBSchoemanRPredictors of long-term outcome in schizophreniaCurr Opin Psychiatry200821217317718332666
   PubMed Web of Science ®Google Scholar
• LappinJMMorganKMorganCGray matter abnormalities associated with duration of untreated psychosisSchizophr Res2006832–314515316448803
   PubMed Web of Science ®Google Scholar
• XiangY-TWangC-YWengY-ZPredictors of relapse in Chinese schizophrenia patients: a prospective, multi-center studySoc Psychiatry Psychiatr Epidemiol201146121325133021046070
   PubMed Web of Science ®Google Scholar
• BarkhofEMeijerCJde SonnevilleLMJLinszenDHde HaanLInterventions to improve adherence to antipsychotic medication in patients with schizophrenia – a review of the past decadeEur Psychiatry201227191821561742
   PubMed Web of Science ®Google Scholar
• CañasFAlptekinKAzorinJMImproving treatment adherence in your patients with schizophrenia: the STAY initiativeClin Drug Investig201333297107
   PubMed Web of Science ®Google Scholar
• BonfioliEBertiLGossCMuraroFBurtiLHealth promotion lifestyle interventions for weight management in psychosis: a systematic review and meta-analysis of randomised controlled trialsBMC Psychiatry20121217822789023
   PubMed Web of Science ®Google Scholar
• FaulknerGCohnTRemingtonGInterventions to reduce weight gain in schizophreniaSchizophr Bull200733365465617449900
   PubMed Web of Science ®Google Scholar
• GabrieleJMDubbertPMReevesRREfficacy of behavioural interventions in managing atypical antipsychotic weight gainObes Rev200910444245519389059
   PubMed Web of Science ®Google Scholar
• MontgomeryWTreuerTYeWDoes participation in a weight control program also improve clinical and functional outcomes for Chinese patients with schizophrenia treated with olanzapine? Value Health2012157A669
   Web of Science ®Google Scholar
• MontgomeryWTreuerTYeWDoes participation in a weight control program also improve clinical and functional outcomes for Chinese patients with schizophrenia treated with olanzapine?Neuropsych Dis Treat2014
   Web of Science ®Google Scholar
• MontgomeryWLiuNAAscher-SvanumHXueTreuerTStenslandMThe personal, societal, and economic burden of schizophrenia in the Peoples Republic of China: implications for antipsychotic therapyClin Outcomes Res20135407418
   PubMedGoogle Scholar
• LiuLYeWXiaoningHWuJMontgomeryWXueHBDifferential resource use and costs among inpatients and outpatients with schizophrenia in Tianjin, ChinaProceedings of the 4th World Congress of Asian PsychiatryBangkok, ThailandAugust 20–23, 2013
   Google Scholar
• XiaoningHWuJLiuLMontgomeryWYeWXueHBHealth care resource utilization and direct medical costs among patients with schizophrenia in Tianjin, ChinaProceedings of the 4th World Congress of Asian PsychiatryBangkok, ThailandAugust 20–23, 2013
   Google Scholar
• ChenHHPhillipsMRChengHMental health law of the People’s Republic of China (English translation with annotations)Shanghai Arch Psychiatry2012246305321
   PubMedGoogle Scholar
• HvistendahlMWorld’s biggest health care system goes under the knifeScience2013339611950550723371991
   PubMed Web of Science ®Google Scholar
• GardnerKNBostwickJRAntipsychotic treatment response in schizophreniaAm J Health Syst Pharm201269211872187923111671
   PubMed Web of Science ®Google Scholar
• HattaKOtachiTSudoYDifference in early prediction of antipsychotic non-response between risperidone and olanzapine in the treatment of acute-phase schizophreniaSchizophr Res20111281–312713521420283
   PubMed Web of Science ®Google Scholar
• EssockSMCovellNHDavisSMStroupTSRosenheckRALiebermanJAEffectiveness of switching antipsychotic medicationsAm J Psychiatry2006163122090209517151159
   PubMed Web of Science ®Google Scholar
• SuarezDHaroJMNovickDPerrinEOchoaSNaberDReasons and outcomes of olanzapine dose adjustments in the outpatient treatment of schizophreniaPharmacopsychiatry200942413514019585391
   PubMed Web of Science ®Google Scholar